Single-dose vaginal clindamycin is not one standardized medication package. In U.S. labeling, Clindesse is a 2% vaginal cream dispensed in a prefilled single-dose applicator, whereas Xaciato is a 2% vaginal gel supplied with a tube and user-filled single-dose applicator. For the broader category, use our vaginal clindamycin guide.
The two products both contain clindamycin as clindamycin phosphate and deliver a labeled single intravaginal treatment, but the formulation, approved patient population, contraindications and specific barrier-contraception warnings differ. The word “single-dose” describes regimen length; it does not establish clinical interchangeability or permission to switch brands.
This page compares the decision-relevant label characteristics of the products rather than giving personalized treatment directions. Brand product context appears on the separate Clindesse guide and Xaciato guide; a clinician should determine which formulation is suitable for a particular patient.
Clindesse is labeled for bacterial vaginosis in nonpregnant women, and Xaciato is indicated for bacterial vaginosis in females 12 years of age and older. Both have a 2% formulation and approximately 100 mg clindamycin in the labeled administered 5 g quantity, yet the vehicle and applicator system are different.
A matched percentage or nominal clindamycin amount should never override those differences. Patients need to compare the specific indication, package, instructions and contraindications, not assume that every clindamycin product with “2%” on the carton represents the same treatment.
| Label feature | Clindesse | Xaciato |
|---|---|---|
| Dosage form | Clindamycin phosphate 2% vaginal cream | Clindamycin phosphate 2% vaginal gel |
| Indication population | Bacterial vaginosis in nonpregnant women | Bacterial vaginosis in females age 12 and older |
| Delivered single dose | Prefilled applicator, about 5 g/100 mg | User-filled applicator, 5 g/100 mg |
| Package system | Single prefilled disposable applicator | 8 g tube plus disposable applicator |
| Barrier warning | Avoid condoms and vaginal diaphragms during use and 5 days after | Avoid polyurethane condoms during use and 7 days after |
| Additional product restriction | Read full cream-specific instructions | Avoid intercourse and vaginal products for 3 days after use |
| Interchangeability | Prescription-specific; not an automatic substitute | Prescription-specific; not an automatic substitute |
Clindesse has a prefilled disposable applicator containing the single cream dose. Xaciato comes in an 8 g tube and a separate single-dose applicator that the patient fills to deliver 5 g of vaginal gel. These details matter when verifying a dispensed carton and interpreting the product-specific instructions.
The exact applicator assembly instructions should be taken from the current patient leaflet, not a third-party picture or another brand’s instructions. See the separate vaginal cream product overview and vaginal gel product overview for formulation-level distinctions.
The Clindesse label describes treatment of bacterial vaginosis in nonpregnant women. Its pregnancy limitation is important when comparing products and is not erased by the fact that other clindamycin products may have different labeling. Pregnancy or possible pregnancy requires individual clinical assessment.
Xaciato’s indication includes female patients age 12 years and older. That statement is an approved population, not permission for self-diagnosis or use without a prescription. If symptoms suggest another condition, a clinician may recommend examination or testing before treatment.
The Clindesse labeling advises against condoms and vaginal contraceptive diaphragms during treatment and for five days afterward because barrier protection may be unreliable. The Xaciato label specifically warns about polyurethane condoms during treatment and for seven days afterward; it identifies latex or polyisoprene condoms as alternatives.
These warnings should not be averaged into a single rule for “vaginal clindamycin.” Xaciato additionally instructs avoiding vaginal intercourse and vaginal products during treatment and for three days after use. Discuss protection against pregnancy and sexually transmitted infections with a clinician if these instructions affect your situation.
Clindamycin can cause antibiotic-associated diarrhea, including C. difficile-associated disease. Both products require attention to significant diarrhea even though they are used intravaginally. Clindesse labeling additionally lists a history of regional enteritis, ulcerative colitis or C. difficile-associated diarrhea as contraindications.
Xaciato lists hypersensitivity to clindamycin or lincomycin as a contraindication. The difference between these label sections is another reason not to assume the products are interchangeable. A prescriber must review the full patient history and current labeling.
An individual’s diagnosis, pregnancy status, age, allergy history, gastrointestinal history and other treatments may change whether either product is appropriate. The clinician also decides whether a recommended alternative regimen is more suitable than a vaginal clindamycin option.
For the condition-level treatment landscape, read clindamycin for bacterial vaginosis. This page is confined to two single-dose product labels, not a recommendation to replace a multiday course or another antibiotic.
Percentage strength describes a product’s concentration but does not capture viscosity, inactive ingredients, applicator design or release characteristics. Those factors can matter to FDA labeling and clinical selection. Pharmacy software may list both products near one another because the ingredient overlaps.
Review the full brand or generic name, route, dosage form and package. An equivalent-looking number on an electronic formulary is only a starting point for a pharmacist’s review, never authorization for the patient to change products.
A pharmacy should dispense the ordered single-dose treatment or clarify a possible substitution directly with the prescriber. Ask whether the electronic order identifies Clindesse cream or Xaciato gel, and whether the box includes the exact administration device specified in its instructions.
For a cross-product purchase checklist, the vaginal clindamycin pharmacy guide covers legitimate dispensing, licensing and patient cost without taking over the therapeutic comparison made here.
A one-dose product is not automatically less expensive than a multiday product. Insurer formularies may handle branded products differently, and the final patient amount may reflect a deductible, copay, pharmacy network, prior authorization or package availability.
Ask for a current, patient-specific estimate under the actual prescribed brand and package. The vaginal clindamycin pricing guide explains factors without posting out-of-date dollar figures or assuming coverage.
For Clindesse, a listing should indicate vaginal cream 2% and a prefilled applicator; for Xaciato, it should identify vaginal gel 2% and the corresponding tube/applicator packaging. A retailer photo may not reflect the actual supplied container, so the pharmacy must confirm the specific product.
If the pharmacy offers “clindamycin 2% vaginal” without naming the dosage form, request clarification. The product name, directions and applicator system determine what is dispensed, not the search result headline.
Persistent, recurrent or changing vaginal symptoms require diagnostic review rather than repeated self-treatment. Seek prompt evaluation for pelvic pain, fever or other concerning symptoms. Similar symptoms may result from candidiasis, sexually transmitted infections or other conditions that are not treated the same way.
If pregnancy is possible, tell the clinician before treatment selection. A one-dose label should not be treated as a convenience shortcut around clinical assessment or follow-up.
Clindesse and Xaciato each have a labeled single-dose regimen, but they have distinct formulations, approved populations and precautions. The safest comparison is one that identifies exactly which feature affects the prescription instead of naming a universal “better” product.
Use this comparison to prepare focused questions about applicators, pregnancy considerations, contraindications and barrier contraception. If you are comparing vaginal routes more broadly, our cream versus ovules comparison addresses another materially different choice.
Yes. Each has a labeled single-dose vaginal regimen for bacterial vaginosis, but the products are not automatically interchangeable.
No. Clindesse is a 2% vaginal cream supplied in a prefilled applicator.
No. Xaciato is a 2% vaginal gel supplied as a tube and a separate user-filled applicator.
The Clindesse U.S. indication specifies nonpregnant women. Pregnancy concerns require direct discussion with a clinician rather than inferring suitability from other clindamycin labels.
The U.S. indication includes female patients age 12 years and older. Treatment still requires a clinician’s prescription.
No. Clindesse provides a five-day warning for condoms and vaginal contraceptive diaphragms; Xaciato specifies a seven-day warning for polyurethane condoms.
No. Matching concentration does not establish product equivalence or substitution permission.
The pharmacist must review prescription restrictions and contact the prescriber when clarification or a product change is needed.
No. Treatment response varies, and ongoing or recurrent symptoms warrant reassessment. The regimen does not guarantee an outcome.